Bayer (BAYN.DE)

Executive Summary

Bayer AG is a diversified life sciences company operating through Pharmaceuticals, Consumer Health, and Crop Science divisions, with a market valuation of approximately $38.2 billion. Despite a strong portfolio of established products including Xarelto (rivaroxaban), Eylea, and crop protection solutions, the company faces significant headwinds from ongoing Roundup litigation, patent expirations, and generic competition. In 2025, Bayer reported modest revenue growth driven by Crop Science and Consumer Health, while Pharmaceuticals faced pressure from declining Xarelto sales due to generic entry in certain markets. The company is actively managing its debt and pursuing legal resolutions, including a proposed class action settlement for Roundup claims, which remains a key overhang on its stock.

Upcoming Catalysts (preview)

• Q3 2026Phase III data readout for asundexian in stroke prevention70% success
• Q2 2026Resolution of Roundup litigation (settlement or court ruling)55% success
• Q4 2026FDA approval of darolutamide for metastatic hormone-sensitive prostate cancer (mHSPC)85% success